Logo

Pfizer Using Metabolon's Cellular Metabolism Tool

Jul 21, 2008
NEW YORK (GenomeWeb News) – Metabolon said today that Pfizer’s Bioprocess R&D Group is using the firm’s metabolomics technology in analyzing cellular metabolism in the biopharmaceutical production process.
 
Pfizer will use the biochemical profiling technology, called mVision, to analyze samples from bioreactors, said Research Triangle Park, NC-based Metabolon. The tool will enable researchers to identify essential nutrients that are depleted and unearth toxic metabolites in the cells.
 
“By monitoring a large number of biochemicals in a bioreactor process, customers can quickly uncover areas for optimization,” John Ryals, president and CEO of Metablon, said in a statement.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.